Source: Latest News from Science Magazine
Chemogenetics—the ability to activate or suppress specific neurons using engineered genes and small molecules—has moved from animal models into human patients, with Chinese researchers reporting seizure reduction in three epilepsy cases. The shift from treating symptoms with pharmaceuticals to rewriting cellular behavior itself opens pathways for conditions like Parkinson's, depression, and chronic pain where precision neural modulation could replace broad-spectrum drugs. Stable patient compliance and delivery remain unsolved problems, but the clinical proof-of-concept signals that targeted brain intervention is moving from theoretical to viable.